DekaBank Deutsche Girozentrale Takes $966,000 Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

DekaBank Deutsche Girozentrale purchased a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 46,000 shares of the company's stock, valued at approximately $966,000. DekaBank Deutsche Girozentrale owned approximately 0.11% of 4D Molecular Therapeutics at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. RA Capital Management L.P. lifted its holdings in shares of 4D Molecular Therapeutics by 35.6% in the third quarter. RA Capital Management L.P. now owns 4,163,211 shares of the company's stock valued at $52,998,000 after purchasing an additional 1,093,680 shares in the last quarter. BlackRock Inc. raised its holdings in 4D Molecular Therapeutics by 14.3% during the second quarter. BlackRock Inc. now owns 2,914,430 shares of the company's stock worth $52,664,000 after acquiring an additional 363,695 shares in the last quarter. State Street Corp raised its holdings in 4D Molecular Therapeutics by 0.4% during the second quarter. State Street Corp now owns 2,050,430 shares of the company's stock worth $37,051,000 after acquiring an additional 8,241 shares in the last quarter. Vanguard Group Inc. raised its holdings in 4D Molecular Therapeutics by 0.6% during the first quarter. Vanguard Group Inc. now owns 1,290,941 shares of the company's stock worth $19,519,000 after acquiring an additional 7,858 shares in the last quarter. Finally, ArrowMark Colorado Holdings LLC raised its holdings in 4D Molecular Therapeutics by 5.1% during the first quarter. ArrowMark Colorado Holdings LLC now owns 1,032,719 shares of the company's stock worth $17,752,000 after acquiring an additional 50,520 shares in the last quarter. 99.27% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Jefferies Financial Group upped their target price on 4D Molecular Therapeutics from $30.00 to $58.00 and gave the stock a "buy" rating in a report on Monday, April 1st. Royal Bank of Canada upped their target price on 4D Molecular Therapeutics from $35.00 to $40.00 and gave the stock an "outperform" rating in a report on Monday. HC Wainwright reiterated a "buy" rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Friday, March 1st. Barclays assumed coverage on 4D Molecular Therapeutics in a report on Monday. They set an "overweight" rating on the stock. Finally, The Goldman Sachs Group reiterated a "buy" rating and set a $81.00 target price on shares of 4D Molecular Therapeutics in a report on Wednesday, February 7th. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $44.22.

4D Molecular Therapeutics Price Performance

NASDAQ:FDMT traded down $0.10 during trading hours on Monday, reaching $26.25. 610,526 shares of the company were exchanged, compared to its average volume of 1,103,500. The company has a market capitalization of $1.34 billion, a P/E ratio of -10.04 and a beta of 2.87. 4D Molecular Therapeutics, Inc. has a 1-year low of $9.44 and a 1-year high of $36.25. The business has a 50 day moving average of $29.32 and a 200 day moving average of $19.86.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.09). The company had revenue of ($0.02) million for the quarter, compared to analyst estimates of $4.67 million. 4D Molecular Therapeutics had a negative return on equity of 34.14% and a negative net margin of 436.30%. As a group, equities research analysts anticipate that 4D Molecular Therapeutics, Inc. will post -3.03 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Scott Bizily sold 8,153 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $31.78, for a total value of $259,102.34. Following the completion of the transaction, the insider now directly owns 1,737 shares in the company, valued at approximately $55,201.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO David Kirn sold 5,696 shares of the stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $18.41, for a total value of $104,863.36. Following the completion of the transaction, the chief executive officer now directly owns 1,151,154 shares in the company, valued at approximately $21,192,745.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Scott Bizily sold 8,153 shares of the firm's stock in a transaction on Monday, April 1st. The stock was sold at an average price of $31.78, for a total value of $259,102.34. Following the transaction, the insider now directly owns 1,737 shares of the company's stock, valued at $55,201.86. The disclosure for this sale can be found here. Insiders sold 147,888 shares of company stock worth $4,134,254 over the last three months. Insiders own 10.70% of the company's stock.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.